SCHEMBL6608580

SCHEMBL6608580

CN(C)S(=O)(=O)c1ccc(C(=O)CBr)cc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.53
PTPN1 P18031 4/20 0.50
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 1/20 0.48
LMNA P02545 3/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GSR P00390 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6406201 0.94 GSK3B (0.47) GSK3BPTPN1MAPTALDH1A1SMN1; SMN2
SCHEMBL13545219 0.84 SMN1; SMN2 (0.51) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL4345155 0.83 HTT (0.58) GSK3BMAPTALDH1A1SMN1; SMN2HSD17B10
Hydrochloric Acid SCHEMBL9863504 0.81 ALDH1A1 (0.49) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL23553765 0.80 MEN1 (0.62) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL30041713 0.80 MEN1 (0.62) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL125350 0.79 GSR (0.59) GSK3BPTPN1GSR
SCHEMBL11543660 0.79 LMNA (0.48) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL5249012 0.79 SMN1; SMN2 (0.57) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL17290764 0.78 ALDH1A1 (0.50) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117355300-A Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic diseases 佛罗里达大学研究基金会公司 2024-01-05 CN disclosed
EP-4277623-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-11-22 EP disclosed
WO-2022155463-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2022-07-21 WO disclosed
WO-2022095989-A1 P300 INHIBITORS AND USE THEREOF IN MEDICINE 贝达药业股份有限公司 2022-05-12 WO disclosed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP disclosed
US-5041567-A Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis BEECHAM GROUP PLC (GB) 1991-08-20 US disclosed
US-4812470-A Antibacterial monic acid derivatives BEECHAM GROUP P.L.C. (GB) 1989-03-14 US disclosed
EP-0087953-B1 ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS BEECHAM GROUP PLC (GB) 1988-04-27 EP disclosed
US-4716169-A INOTROPIC AGENTS DR. KARL THOMAE GMBH (DE) 1987-12-29 US disclosed
EP-0185345-A1 Imidazo derivatives, their preparation and medicines containing them Dr. Karl Thomae GmbH (DE) 1986-06-25 EP disclosed
EP-0185346-A2 Imidazo derivatives, their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1986-06-25 EP disclosed
EP-0087953-A2 Antibacterial 1-normon-2-yl-heterocyclic compounds BEECHAM GROUP PLC (GB) 1983-09-07 EP disclosed